

Supplementary References

- S1 Petrecca K, Guiot M-C, Panet-Raymond V, et al. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. *J Neurooncol* 2013;111:19–23. doi:10.1007/s11060-012-0983-4
- S2 Berrington A, Voets NL, Larkin SJ, et al. A comparison of 2-hydroxyglutarate detection at 3 and 7 T with long-TE semi-LASER. *NMR Biomed* 2018;31. doi:10.1002/nbm.3886
- S3 Emir UE, Larkin SJ, De Pennington N, et al. Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. *Cancer Res* 2016;76:43–9. doi:10.1158/0008-5472.CAN-15-0934
- S4 Verburg N, Koopman T, Yaqub MM, et al. Improved detection of diffuse glioma infiltration with imaging combinations: A diagnostic accuracy study. *Neuro Oncol* 2020;22:412–22. doi:10.1093/neuonc/noz180
- S5 Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma a systematic review and meta-Analysis. *JAMA Oncol* 2016;2:1460–9. doi:10.1001/jamaoncol.2016.1373
- S6 Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor with Survival Within Molecular Subgroups of Patients with Newly Diagnosed Glioblastoma. *JAMA Oncol* 2020;6:495–503. doi:10.1001/jamaoncol.2019.6143
- S7 Cordova JS, Shu H-KG, Liang Z, et al. Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. *Neuro Oncol* 2016;:now036. doi:10.1093/neuonc/now036
- S8 Livermore LJ, Isabelle M, Bell IM, et al. Raman spectroscopy to differentiate between fresh tissue samples of glioma and normal brain: a comparison with 5-ALA–induced fluorescence-guided surgery. *J Neurosurg* 2020;:1–11. doi:10.3171/2020.5.jns20376
- S9 Livermore LJ, Isabelle M, Bell I Mac, et al. Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy. *Neuro-Oncology Adv* 2019;1:vdz008. doi:10.1093/oaajnl/vdz008
- S10 Hollon TC, Pandian B, Adapa AR, et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. *Nat. Med.* 2020;26:52–8. doi:10.1038/s41591-019-0715-9
- S11 Jermyn M, Mok K, Mercier J, et al. Intraoperative brain cancer detection with Raman spectroscopy in humans. *Sci Transl Med* 2015;7:274ra19. doi:10.1126/scitranslmed.aaa2384
- S12 Sughrue ME, Sheean T, Bonney PA, et al. Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework. *Neurosurg Focus* 2015;38:E11. doi:10.3171/2014.12.FOCUS14726
- S13 Quick J, Gessler F, Dutzmann S, et al. Benefit of tumor resection for recurrent glioblastoma. *J Neurooncol* 2014;117:365–72. doi:10.1007/s11060-014-1397-2
- S14 Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. *J Neurosurg* 2012;117:1032–8. doi:10.3171/2012.9.JNS12504
- S15 McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. *J Neurosurg* 2009;110:156–62. doi:10.3171/2008.4.17536
- S16 Oppenlander ME, Wolf AB, Snyder LA, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. *J Neurosurg* 2014;120:846–53. doi:10.3171/2013.12.JNS13184
- S17 Ringel F, Pape H, Sabel M, et al. Clinical benefit from resection of recurrent glioblastomas: Results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. *Neuro Oncol* 2016;18:96–104. doi:10.1093/neuonc/nov145
- S18 Suchorska B, Weller M, Tabatabai G, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. *Neuro Oncol* 2016;18:nov326-. doi:10.1093/neuonc/nov326
- S19 Yong RL, Wu T, Mihatov N, et al. Residual tumor volume and patient survival following

- reoperation for recurrent glioblastoma. *J Neurosurg* 2014;121:1–8. doi:10.3171/2014.6.JNS132038
- S20 Brennan PM, Borchert R, Coulter C, et al. Second surgery for progressive glioblastoma: a multi-centre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice. *J Neurooncol* 2021;:1–9. doi:10.1007/s11060-021-03748-0
- S21 Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* (80-) 2008;321:1807–12. doi:10.1126/science.1164382
- S22 Von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. In: *Brain Pathology. Brain Pathol* 2011. 74–87. doi:10.1111/j.1750-3639.2010.00454.x
- S23 Han S, Liu Y, Cai SJ, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. *Br J Cancer* 2020;122:1580–9. doi:10.1038/s41416-020-0814-x
- S24 Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. *Nature* 2021;:1–6. doi:10.1038/s41586-021-03363-z
- S25 Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. *Nat. Rev. Cancer.* 2004;4:296–307. doi:10.1038/nrc1319
- S26 Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352:997–1003. doi:10.1056/NEJMoa043331
- S27 Brennan CW, Verhaak RGW, McKenna A, et al. The Somatic Genomic Landscape of Glioblastoma. *Cell* 2014;155:462–77. doi:10.1016/j.cell.2013.09.034.The
- S28 Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. *Cancer Res* 2006;66:3987–91. doi:10.1158/0008-5472.CAN-06-0127
- S29 Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. *J Clin Oncol* 2009;27:5743–50. doi:10.1200/JCO.2009.23.0805
- S30 Lee A, Arasaratnam M, Chan DLH, et al. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. *Cochrane Database Syst. Rev.* 2020;2020. doi:10.1002/14651858.CD013238.pub2
- S31 Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. *Lancet Oncol* 2012;13:916–26. doi:10.1016/S1470-2045(12)70265-6
- S32 Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. *N Engl J Med* 2017;376:1027–37. doi:10.1056/nejmoa1611977
- S33 Perry JR, Bélanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. *J Clin Oncol* 2010;28:2051–7. doi:10.1200/JCO.2009.26.5520
- S34 Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? *Cancer Treat. Rev.* 2020;87. doi:10.1016/j.ctrv.2020.102029
- S35 Diaz RJ, Ali S, Qadir MG, et al. The role of bevacizumab in the treatment of glioblastoma. *J. Neurooncol.* 2017;133:455–67. doi:10.1007/s11060-017-2477-x
- S36 Choi BD, Yu X, Castano AP, et al. Bispecific T-Cell Engager -Armored Chimeric Antigen Receptor T Cells Overcome Antigen Escape From EGFRvIII-Targeted Therapy For Glioblastoma. *Neurosurgery* 2019;66. doi:10.1093/neuros/nyz310_154
- S37 Hegde M, Grada Z, Pignata A, et al. A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma. *J Immunother Cancer* 2015;3:O3. doi:10.1186/2051-1426-3-S2-O3
- S38 Chiocca EA, Aguilar LK, Bell SD, et al. Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma. *J Clin Oncol* 2011;29:3611–9. doi:10.1200/JCO.2011.35.5222
- S39 Zhu Z, Gorman MJ, McKenzie LD, et al. Zika virus has oncolytic activity against glioblastoma stem cells. *J Exp Med* 2017;214:2843–57. doi:10.1084/jem.20171093
- S40 Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia

- enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. *Neuro Oncol* 2011;13:324–33. doi:10.1093/neuonc/noq157
- S41 Wen PY, Reardon DA, Armstrong TS, et al. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. *Clin Cancer Res* 2019;25:5799–807. doi:10.1158/1078-0432.CCR-19-0261
- S42 Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. *Neuro Oncol* 2015;17:1064–75. doi:10.1093/neuonc/nou307
- S43 Woroniecka K, Chongsathidkiet P, Rhodin KE, et al. T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma. *Clin Cancer Res* 2018;:clincanres.1846.2017. doi:10.1158/1078-0432.CCR-17-1846
- S44 Brown NF, Ng SM, Brooks C, et al. A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: The Ipi-Glio trial protocol. *BMC Cancer* 2020;20:198. doi:10.1186/s12885-020-6624-y
- S45 Kirson ED, Dbalý V, Tovaryš F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. *Proc Natl Acad Sci U S A* 2007;104:10152–7. doi:10.1073/pnas.0702916104
- S46 Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. *Eur J Cancer* 2012;48:2192–202. doi:10.1016/J.EJCA.2012.04.011
- S47 Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma a secondary analysis of a randomized clinical trial. *JAMA Oncol* 2018;4:495–504. doi:10.1001/jamaoncol.2017.5082
- S48 Lassman AB, Joanta-Gomez AE, Pan PC, et al. Current usage of tumor treating fields for glioblastoma. *Neuro-Oncology Adv* 2020;2. doi:10.1093/nojnl/vdaa069
- S49 Cloughesy TF, Lassman AB. NovoTTF: Where to go from here? *Neuro Oncol* 2017;19:605–8. doi:10.1093/neuonc/nox014
- S50 Chow KKH, Hara W, Lim M, et al. Combining immunotherapy with radiation for the treatment of glioblastoma. *J Neurooncol* 2015;:459–64. doi:10.1007/s11060-015-1762-9
- S51 Samson A, Scott KJ, Taggart D, et al. Intravenous Delivery of Oncolytic Reovirus to Brain Tumor Patients Immunologically Primes for Subsequent Checkpoint Blockade. *Sci Transl Med* 2018;7577:eaam7577.
- S52 Wen PY, Chang SM, Lamborn KR, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. *Neuro Oncol* 2014;16:567–78. doi:10.1093/neuonc/not247